Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
malaria vaccine (messenger RNA-lipid nanoparticle)
- Development stage
- Preclinical
- Lead developer
- eTheRNA immunotherapies
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
The malaria vaccine (messenger RNA-lipid nanoparticle) is an investigational mRNA-based vaccine candidate being developed by eTheRNA immunotherapies for the prevention of malaria. The vaccine utilizes a messenger RNA (mRNA) platform encapsulated within lipid nanoparticles (LNPs) to deliver genetic instructions for malaria-specific antigens into host cells. Once expressed, these antigens are intended to stimulate a robust and protective immune response, including both antibody and T-cell mediated immunity, against *Plasmodium* parasites. The program is currently in the preclinical stage of development and is designed for intramuscular administration.
- Other names
- mRNA-LNP Malaria VaccineMalaria vaccine
Beyond the preview
Go deeper on malaria vaccine (messenger RNA-lipid nanoparticle).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on malaria vaccine (messenger RNA-lipid nanoparticle).